The association of lipoprotein lipase PvuII polymorphism and niacin intake in the prevalence of metabolic syndrome: a KMSRI-Seoul study

详细信息    查看全文

• 作者：Eunjung Shin (1)
  Na-Young Park (2)
  Yangsoo Jang (3)
  Hyunhee Oh (4)
  Jayoung Jeong (5)
  Yunsook Lim (2)
  Myoungsook Lee (1) (6)
  
• 关键词：LPL mass ; LPL PvuII gene polymorphism ; Metabolic syndrome ; Niacin ; Recommended intake
• 刊名：Genes & Nutrition
• 出版年：2012
• 出版时间：April 2012
• 年：2012
• 卷：7
• 期：2
• 页码：331-341
• 全文大小：332KB
• 参考文献：1. Ahn YI, Kamboh MI, Hamman RF, Cole SA, Ferrell RE (1993) Two DNA polymorphisms in the lipoprotein lipase gene and their associations with factors related cardiovascular disease. J Lipid Res 34:421-28
  2. Al-Shaer MH, AbuSabha HS (2004) Are the effects of nicotinic acid on insulin resistance precipitated by abnormal phosphorous metabolism? Lipids Health Dis 3:23 CrossRef
  3. Botstein D, White RL, Skolnick M, Davis RW (1980) Construction of a genetic linkage map in man using restriction fragment length polymorphisms. Am J Hum Genet 32:314-31
  4. Canner PL, Furberg CD, McGovern ME (2006) Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 97:477-79 CrossRef
  5. Chamberlain JC, Thorn JA, Oka K, Galton DJ, Stocks J (1989) DNA polymorphisms at the lipoprotein lipase gene: Associations in normal and hypertriglyceridaemic subjects. Atherosclerosis 79:85-1 CrossRef
  6. Chapman MJ, Redfern JS, McGovern ME, Giral P (2010) Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 126:314-45 CrossRef
  7. Chung HJ, Yoon YM, Han TH, Park H, Song J, Kim JQ (1999) Polymorphisms at the lipoprotein lipase gene: possible associations with coronary artery disease and blood lipid levels in Koreans. Korean J Clin Pathol 19:617-23
  8. Duman BS, Turkoqlu C, Akpinar B, Guden M, Vertii A, Dak E, Cagatay P, Gunay D, Buyukdevrim AS (2004) Lipoprotein lipase gene polymorphism and lipid profile in coronary artery disease. Arch Pathol Lab Med 128:869-74
  9. Ekelund U, Anderssen S, Andersen LB, Riddoch CJ, Sardinha LB, Luan J, Froberg K, Brage S (2009) Prevalence and correlates of the metabolic syndrome in a population-based sample of European youth. Am J Clin Nutr 89:90-6 CrossRef
  10. Fisher KL, FitzGerald GA, Lawn RM (1987) Two polymorphisms in the human lipoprotein lipase (LPL) gene. Nucleic Acids Res 15:7657 CrossRef
  11. Food and Nutrition Board, Insitute of Medicine (IOM) (1998) Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin and choline. The National Academies Press, Washington, DC, pp 123-49
  12. Friedewald VE Jr, Gotto AM Jr (2000) Case 1: a patient with elevated low-density lipoprotein cholesterol. Am J Cardiol 85:131 CrossRef
  13. Gerdes C, Gerdes LU, Hansen PS, Faergeman O (1995) Polymorphisms in the lipoprotein lipase gene and their associations with plasma lipid concentrations in 40-year-old Danish men. Circulation 92:1765-769
  14. Gotoda T, Senda M, Murase T, Yamada N, Takaku F, Furuichi Y (1989) Gene polymorphism identified by PvuII in familial lipoprotein lipase deficiency. Biochem Biophys Res Commun 164:1391-396 CrossRef
  15. Haung TT, Ball GD, Franks PW (2007) Metabolic syndrome in youth: current issues and challenges. Appl Physiol Nutr Metab 32:13-2 CrossRef
  16. Hitsumoto T, Ohsawa H, Uchi T, Noike H, Kanai M, Yoshinuma M, Miyashita Y, Watanabe H, Shirai K (2000) Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis 153:391-96 CrossRef
  17. Javorsky M, Kozarova M, Salagovic J, Tkac I (2006) Relationship among urinary albumin excretion rate, lipoprotein lipase PvuII polymorphism and plasma fibrinogen in type 2 diabetic patients. Physiol Res 55:55-2
  18. Kamanna VS, Kashyap ML (2008) Mechanism of action of niacin. Am J Cardiol 101:20-6 CrossRef
  19. Kastelein JJ, Jukema JW, Zwinderman AH, Clee S, van Boven AJ, Jansen H, Rabelink TJ, Pters RJ, Lie KI, Liu G, Bruschke AV, Havden MR (2000) Lipoprotein lipase activity is associated with severity of angina pectoris. REGRESS Study Group. Circulation 102:1629-633
  20. Kobayashi J, Hashimoto H, Fukamachi I, Tashiro J, Shirai K, Saito Y, Yoshida S (1993) Lipoprotein lipase mass and activity in severe hypertriglyceridemia. Clin Chim Acta 216:113-23 CrossRef
  21. Kobayashi J, Nohara A, Kawashiri MA, Inazu A, Koizumi J, Nakajima K, Mabuchi H (2007) Serum lipoprotein lipase mass: clinical significance of its measurement. Clin Chim Acta 378:7-2 CrossRef
  22. Korea Center for Disease Control and Prevention (2007) In-depth analysis on the 3rd (2005) Korea health and nutrition examination survey—nutrition survey. Korea Health Industry Development Institute, Seoul, pp 1-52
  23. Korean Nutrition Society (2005) Dietary reference intakes for Koreans. Kookjin Publishing Co, Seoul
  24. Kosaka T, Yoshino J, Inui K, Wakabayashi T, Okushima K, Kobayashi T, Miyoshi H, Nakamura Y, Hayashi S, Shiraishi T, Watanabe M, Yamamoto T, Nakahara A, Katoh T (2006) Impact of lipoprotein lipase gene polymorphisms on ulcerative colitis. World J Gastroenterol 12:6325-330
  25. Levesque J, Lamarche B (2008) The metabolic syndrome: definitions, prevalence and management. J Nutrigenet Nutrigenomics 1:100-08 CrossRef
  26. Lottenberg SA, Glezer A, Turatti LA (2007) Metabolic syndrome: identifying the risk factors. J Pediatr (Rio J) 83:204-08 CrossRef
  27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function form fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-19 CrossRef
  28. McKenney J (2003) Niacin for dyslipidemia: considerations in product selection. Am J Health Syst Pharm 60:995-005
  29. McKenney J (2004) New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 164:697-05 CrossRef
  30. Merkel M, Eckel RH, Goldberg IJ (2002) Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res 43(12):1997-006
  31. Ministry of Health and Welfare (2006) The Third Korea National Health and Nutrition Examination Survey (KNHANES III), 2005 health examination. Ministry of Health and Welfare, Seoul
  32. Miyashita Y, Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, Watanabe H (2002) Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy. Diabetes Res Clin Pract 56:181-87 CrossRef
  33. Motta M, Bennati E, Cardillo E, Passamonte M, Ferlito L, Malaguarnera M (2009) The metabolic syndrome (MS) in the elderly: considerations on the diagnostic criteria of the International Diabetes Federation (IDF) and some proposed modifications. Arch Gerontol Geriatr 48:380-84 CrossRef
  34. Narita S, Tsuchiya N, Wang L, Matsuura S, Ohyama C, Satoh S, Sato K, Ogawa O, Habuchi T, Kato T (2004) Association of lipoprotein lipase gene polymorphism with risk of prostate cancer in a Japanese population. Int J Cancer 112:872-76 CrossRef
  35. National Cholesterol Education Program (2001) The third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Executive Summary. NIH publication no. 01-3095. National Heart, Lung, and Blood Institute, Bethesda
  36. National Coordinating Committee on Food and Nutrition (NCCN) (2005) Ministry of health Malaysia, Putrajaya, chap. 8: niacin (Vitamin B3), pp 81-9
  37. Pan WH, Yeh WT, Weng LC (2008) Epidemiology of metabolic syndrome in Asia. Asia Pac J Clin Nutr 17:37-2
  38. Park JS, Sung JD, Chae IH, Kim HS, Ju JR, Son DW, Oh BH, Lee MM, Park YB, Choi YS, Lee YW (2000) Effect of lipoprotein lipase gene polymorphism on lipid profile and body mass index in healthy Korean adult. Korean J Med 58:57-6
  39. Rosenson RS (2009) Management of non-high-density lipoprotein abnormalities. Atherosclerosis 207:328-35 CrossRef
  40. Saiki A, Oyama T, Endo K, Ebisuno M, Ohira M, Koide N, Murano T, Miyashita Y, Shirai K (2007) Preheparin serum lipoprotein lipase mass might be a biomarker of metabolic syndrome. Diabetes Res Clin Pract 76:93-01 CrossRef
  41. Sakayama K, Masuno H, Kidani T, Matsuda Y, Yamamoto H, Okuda H (2001) Synthesis of active high mannose-type lipoprotein lipase in human adipose tissues. Atherosclerosis 155:29-5 CrossRef
  42. Sepetiba RJ, Andrade J, Hirata RD, Hirata MH, Sepetiba CR, Nakamura Y, Matsumoto LO, Cavalli SA, Bertolami MC (2007) Lipoprotein lipase PvuII polymorphism is associated with variations in serum lipid levels in non-diabetic pregnant women. Braz J Med Biol Res 40:919-26 CrossRef
  43. Shen H, Yu S, Xu Y, Yu R, Jiang W, Chen W (2000) DNA polymorphism of PvuII site in the lipoprotein lipase gene in patients with type 2 diabetes mellitus. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 17:24-7
  44. Song HJ, Kim JM, Kim J (1999) Association of lipoprotein lipase gene polymorphisms with plasma lipids in ischemic stroke patients. J Korean Neurol Assoc 17:340-46
  45. Susleyici Duman B, Ozturk M, Yilmazer S, Cagatay P, Hatemi H (2005) DNA polymorphism of PvuII site in the lipoprotein lipase gene in patients with non-insulin dependent diabetes mellitus. Cell Biochem Funct 23:399-04 CrossRef
  46. Tan CE, Ma S, Wai D, Chew SK, Tai ES (2004) Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 27:1182-186 CrossRef
  47. Ukkola O, Savolainen MJ, Salmela PI, von Dickhoff K, Kesaniemi YA (1995) DNA polymorphisms at the lipoprotein lipase gene are associated with macroangiopathy in type 2 (non-insulin-dependent) diabetes mellitus. Atherosclerosis 115:99-05 CrossRef
  48. Ukkola O, Garenc C, Perusse L, Bergeron J, Despres JP, Rao DC, Bouchard C (2001) Genetic variation at the lipoprotein lipase locus and plasma lipoprotein and insulin levels in the Quebec Family Study. Atherosclerosis 158:199-06 CrossRef
  49. Vittone F, Chait A, Morse JS, Fish B, Brown BG, Zhao XQ (2007) Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: a subgroup analysis of the HDL-Atherosclerosis Treatment Study (HATS). J Clin Lipidol 1:203-10 CrossRef
  50. Wacker MJ, Godard MP, McCabe EH, Donnelly JE, Kelly JK (2008) Sex difference in the association of the angiotensin converting enzyme I/D polymorphism and body mass index. Med Sci Monit 14:353-57
  51. Watanabe H, Miyashita Y, Murano T, Hiroh Y, Itoh Y, Shirai K (1999) Preheparin serum lipoprotein lipase mass level: the effects of age, gender, and types of hyperlipidemias. Atherosclerosis 145:45-0 CrossRef
  52. Willett WC, Howe GR, Kushi LH (1997) Adjustment for total energy intake in epidemiologic studies. Am J Clin Nutr 65:1220-228
  53. Wittrup HH, Tybjaerj-Hansen A, Nordestgaard BG (1999) Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 99:2901-907
  54. World Health Organization and Food and Agriculture Organization of the United Nations (2004) Vitamin and mineral requirements in human nutrition. 2nd edn. World Health Organization, Geneva, pp 173-75
  55. Xu E, Li W, Zhan L, Guan G, Wang X, Chen S, Shi Y (2008) Polymorphisms of the lipoprotein lipase gene are associated with atherosclerotic cerebral infarction in the Chinese. Neuroscience 155:403-08 CrossRef
  
• 作者单位：Eunjung Shin (1)
  Na-Young Park (2)
  Yangsoo Jang (3)
  Hyunhee Oh (4)
  Jayoung Jeong (5)
  Yunsook Lim (2)
  Myoungsook Lee (1) (6)
  
  1. Department of Food and Nutrition, Sungshin Women’s University, #249-1, 3-ga, Dongsun-dong, Sungbuk-ku, Seoul, 136-742, Korea
  2. Department of Food and Nutrition, Kyung Hee University, #1 Hoegi-dong, Dongdaemun-gu, Seoul, 130-701, Korea
  3. Division of Cardiology, Cardiovascular Genome Center, Yonsei University College of Medicine, Seoul, 120-752, Korea
  4. Department of Cellular and Molecular Physiology and Metabolism, Lee Gil Ya Cancer and Diabetes Institute, Gachon University of Medicine and Science, Incheon, 406-840, Korea
  5. Nutrition and Functional Food Research Division, Korea Food and Drug Administration, Cheongwon, Korea
  6. Research Institute of Obesity Science, Sungshin Women’s University, Seoul, 136-742, Korea
  
• ISSN：1865-3499

文摘

Lipoprotein lipase (LPL) polymorphism correlated with LPL activity is associated with plasma lipid and lipoprotein levels. We aimed to investigate the frequency of LPL PvuII polymorphism and effects of LPL PvuII polymorphism and niacin intake on the prevalence of metabolic syndrome (MetSyn) in Koreans. Lifestyle questionnaires, anthropometry, and dietary records were completed, and LPL PvuII polymorphism, LPL mass, and lipid profiles were determined in 548 Koreans (MetSyn: 278, Non-MetSyn: 270). The MetSyn group showed a significantly lower frequency of P1P1 (wild type) and a higher frequency of P1P2 (hetero type) than the non-MetSyn group. The P2P2 (mutant type) group significantly showed lower levels of HDLc and LPL mass and a higher level of TG than the P1P1 group. As niacin intake increased, LPL mass decreased in the P2P2?group (r 2?=?0.07). In particular, the lowest niacin intake group (?4.82?mg/day) increased more than 3 times with regard to a higher risk of MetSyn than the others in the P2P2 mutant groups. However, the MetSyn risk declined 74% at the optimal levels of niacin intake (14.83-7.80?mg/day) in the P2P2?group compared to those of the P1 allele group. The findings indicate that optimal levels of niacin intake effectively decreased Korean MetSyn prevalence in the P2P2 mutant group.